CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $412.82M |
| Gross Profit (TTM) | $284.37M |
| EBITDA | $2.32M |
| Operating Margin | 1.53% |
| Return on Equity | -2.37% |
| Return on Assets | -1.80% |
| Revenue/Share (TTM) | $7.90 |
| Book Value | $6.12 |
| Price-to-Book | 6.64 |
| Price-to-Sales (TTM) | 5.05 |
| EV/Revenue | 4.652 |
| EV/EBITDA | 346.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 39.00% |
| Shares Outstanding | $51.66M |
| Float | $49.25M |
| % Insiders | 3.42% |
| % Institutions | 101.72% |
Volatility is currently expanding
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of Car.
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.
The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDNA and any ticker you trade — then tracks every position and per-strategy win rate.
